Controls pain in procedures involving the male and female urethra, for topical treatment…. ANDA 40433, held by Sentiss. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 40433 (Lidocaine Hydrochloride), held by Sentiss, was first approved by FDA on Feb 12, 2003, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine HCl 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 12, 2003 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride2% · jelly;topical | Lidocaine Hydrochloride | Rx |
| Aug 27, 2025 | Supplement 20Manufacturing | Approved | None posted |
| Mar 25, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Mar 10, 2017 | Supplement 12Manufacturing | Approved | None posted |
| Feb 12, 2003 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters